{"id":9292,"date":"2025-12-04T14:10:20","date_gmt":"2025-12-04T11:10:20","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9292"},"modified":"2025-12-04T14:10:20","modified_gmt":"2025-12-04T11:10:20","slug":"early-tavr-ultra-short-summary","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/early-tavr-ultra-short-summary\/","title":{"rendered":"EARLY TAVR \u2013 Ultra-Short Summary"},"content":{"rendered":"<div>EARLY TAVR \u2013 Ultra-Short Summary<\/div>\n<div><\/div>\n<div>Source:<\/div>\n<div>Medical News (29 Oct 2025), based on EuroPCR 2025 analyses and TCT Late-Breaking Trial presentations ;<\/div>\n<div>original EARLY TAVR publications in The New England Journal of Medicine (NEJM) and JACC: Cardiovascular Interventions (2024)<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div><span> 1. Early TAVR is superior:<\/span><\/div>\n<div>Reduced death\/stroke\/unplanned CV hospitalization (26.8% vs 45.3%).<\/div>\n<div>(NEJM)<\/div>\n<div><span> 2. Fewer hospitalizations:<\/span><\/div>\n<div>Unplanned CV admissions almost halved (20.9% vs 41.7%).<\/div>\n<div>(NEJM)<\/div>\n<div><span> 3. Better quality of life:<\/span><\/div>\n<div>Favorable outcomes at 2 years: 86.6% vs 68%.<\/div>\n<div>(NEJM)<\/div>\n<div><span> 4. Waiting is unsafe:<\/span><\/div>\n<div>Surveillance patients rapidly deteriorated:<\/div>\n<div>25% needed TAVR at 6 months, 71% by 2 years.<\/div>\n<div>(NEJM)<\/div>\n<div><span> 5. Delayed intervention increases cardiac damage &amp; costs:<\/span><\/div>\n<div>Emergency\/urgent TAVR linked to worse outcomes and much higher Medicare costs.<\/div>\n<div>(JACC Interventions)<\/div>\n<div><\/div>\n<div>Conclusion:<\/div>\n<div>Early TAVR for severe asymptomatic AS prevents deterioration, improves outcomes, and is more cost-effective than \u201cwatchful waiting.\u201d<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.tctmd.com\/news\/early-tavi-improves-prognosis-asymptomatic-no-matter-extent-cardiac-damage\">https:\/\/www.tctmd.com\/news\/early-tavi-improves-prognosis-asymptomatic-no-matter-extent-cardiac-damage<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EARLY TAVR \u2013 Ultra-Short Summary Source: Medical News (29 Oct 2025), based on EuroPCR 2025 analyses and TCT Late-Breaking Trial presentations ; original EARLY TAVR publications in The New England Journal of Medicine (NEJM) and JACC: Cardiovascular Interventions (2024) Keynotes: 1. Early TAVR is superior: Reduced death\/stroke\/unplanned CV hospitalization (26.8% vs 45.3%). (NEJM) 2. Fewer [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9292","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9292"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9292\/revisions"}],"predecessor-version":[{"id":9293,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9292\/revisions\/9293"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}